NDA 020793 · Hikma
Cafcit
Caffeine Citrate · Intravenous, Oral
Priority reviewOrphanLast checked: Nov 20, 2026Latest source record: Mar 2, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1999
Sep 21, 1999
Approved uses
2
Original approval plus efficacy supplements
Registered trials
411
59 Phase 3, 38 recruiting
FAERS reports
2,330
2,271 serious, 1,231 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 8, 2024.
INDICATIONS AND USAGE Caffeine Citrate Injection is indicated for the treatment of apnea of prematurity.
Mechanism: Mechanism of Action Caffeine is structurally related to other methylxanthines, theophylline, and theobromine. It is a bronchial smooth muscle relaxant, a CNS stimulant, a cardiac muscle stimulant, and a diuretic. Although the mechanism of action of caffeine in apnea of prematurity is not known, several mechanisms have been hypothesized. These include: (1) stimulation of the respiratory center, (2) increased minute ventilation, (3) decreased threshold to hypercapnia, (4) increased response to hypercapnia, (5) increased skeletal muscle tone, (6) decreased diaphragmatic fatigue, (7) increased...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 12, 2000 Supplement 1 · Efficacy LetterLabel
- Sep 21, 1999 Original approval · Type 2 - New Active Ingredient · priority review ReviewLetterLabel
2 products under this application
- CAFCIT · CAFFEINE CITRATE EQ 30MG BASE/3ML (EQ 10MG BASE/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
- CAFCIT · CAFFEINE CITRATE EQ 30MG BASE/3ML (EQ 10MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Caffeine" as an intervention, any sponsor and status, largest first.
- PLatform for Adaptive Trials In Perinatal UnitS - [Core Protocol]Pivotal-lookingNot yet recruiting
University of MelbourneAcademic, hospital or other
NCT06461429 · 100,000 participants (planned) · Start Nov 1, 2025 · Primary completion Dec 31, 2050
Drug: Erythromycin; Amoxicillin and Erythromycin and 4 more · For: Preterm Birth
- Reducing Mortality in Adults With Advanced HIV Disease (REVIVE)Pivotal-lookingRecruiting
Population Health Research InstituteAcademic, hospital or other
NCT05580666 · 8,000 participants (planned) · Start May 8, 2023 · Primary completion Nov 30, 2028
Drug: Azithromycin Oral Tablet; Placebo oral tablet · For: HIV Disease Progression
Sites: Abidjan, Côte d’Ivoire; Ādama, Ethiopia; Āsela, Ethiopia · 52 sites in all
- Caffeine Citrate to Improve Neonatal Outcomes.Pivotal-lookingNot yet recruiting
University of MelbourneAcademic, hospital or other
NCT06972849 · 3,900 participants (planned) · Start Oct 2025 · Primary completion Dec 2029
Drug: Caffeine citrate · For: Apnea of Prematurity
- Coated or Chewable Aspirin and a Hybrid Strategy to Mitigate Adverse Effects of Air Pollution in Stable Atherosclerotic DiseasePivotal-lookingRecruiting
Rajaie Cardiovascular Medical and Research CenterAcademic, hospital or other
NCT06541691 · 3,000 participants (planned) · Start Mar 6, 2024 · Primary completion Mar 30, 2026
Drug: Enteric-coated aspirin; Plain aspirin · For: Atherosclerotic Cardiovascular Disease; Coronary Artery Disease; Ischemic Heart Disease and 4 more
Sites: Tehran, Iran
- Caffeine for Apnea of Prematurity (CAP)Pivotal-lookingCompleted
McMaster UniversityAcademic, hospital or other
NCT00182312 · 2,000 participants (planned) · Start Oct 1999 · Primary completion Mar 2007
Drug: Caffeine citrate injection · For: Apnea of Prematurity
Sites: Brooklyn, New York; Canberra, Australia; Adelaide, Australia · 34 sites in all
- Acetylsalicylic Acid (ASA) + Paracetamol + Caffeine Combination Compared With ASA + Paracetamol as Well as ASA, Paracetamol, and Caffeine in Headache PatientsPivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT02183688 · 1,889 participants · Start Sep 1998 · Primary completion Jan 2003
Drug: Low dose ASA; High dose ASA and 4 more · For: Migraine Disorders
- Pragmatic Evaluation of Respiratory Distress Syndrome Treatment in AfricaPivotal-lookingRecruiting
Indiana UniversityAcademic, hospital or other
NCT06554522 · 1,512 participants (planned) · Start Jan 1, 2025 · Primary completion Sep 30, 2027
Drug: Surfactant · For: Respiratory Distress Syndrome in Premature Infant; RDS of Prematurity; Surfactant Deficiency Syndrome Neonatal and 1 more
Sites: Bangui, Central African Republic; Accra, Ghana; Kumasi, Ghana · 8 sites in all
- Paracetamol Vs Caffeine Vs Codeine in the Management of Post Traumatic Pain in EmergenciesPivotal-lookingCompleted
University of MonastirAcademic, hospital or other
NCT05229965 · 1,500 participants · Start Nov 1, 2022 · Primary completion Jun 27, 2023
Drug: Paracetamol; Paracetamol Codeine and 1 more · For: Acute Pain Due to Trauma
Sites: Monastir, Tunisia
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- pemphigus1,007
- hepatic enzyme increased974
- glossodynia972
- pericarditis960
- alopecia954
- hand deformity950
- joint swelling944
- anti-cyclic citrullinated peptide antibody positive931
- rheumatoid arthritis931
- arthropathy925
- discomfort925
- pain924
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 8 |
| 2007 | 20 |
| 2008 | 61 |
| 2009 | 19 |
| 2010 | 34 |
| 2011 | 45 |
| 2012 | 47 |
| 2013 | 11 |
| 2014 | 8 |
| 2015 | 9 |
| 2016 | 10 |
| 2017 | 19 |
| 2018 | 113 |
| 2019 | 67 |
| 2020 | 108 |
| 2021 | 234 |
| 2022 | 265 |
| 2023 | 268 |
| 2024 | 407 |
| 2025 | 374 |
| 2026 | 202 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- The effect of caffeine on subsequent sleep: A systematic review and meta-analysis.
Gardiner C, Weakley J, Burke LM, et al. · Sleep Med Rev 2023 · Meta-Analysis, Systematic Review
- The effects of caffeine intake on weight loss: a systematic review and dos-response meta-analysis of randomized controlled trials.
Tabrizi R, Saneei P, Lankarani KB, et al. · Crit Rev Food Sci Nutr 2019 · Meta-Analysis, Systematic Review
- Effects of Caffeine Intake on Endurance Running Performance and Time to Exhaustion: A Systematic Review and Meta-Analysis.
Wang Z, Qiu B, Gao J, et al. · Nutrients 2022 · Meta-Analysis, Systematic Review
- Effects of Tea (Camellia sinensis) or its Bioactive Compounds l-Theanine or l-Theanine plus Caffeine on Cognition, Sleep, and Mood in Healthy Participants: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Payne ER, Aceves-Martins M, Dubost J, et al. · Nutr Rev 2025 · Systematic Review, Meta-Analysis
- Coffee, Caffeine, and Health Outcomes: An Umbrella Review.
Grosso G, Godos J, Galvano F, et al. · Annu Rev Nutr 2017 · Meta-Analysis, Systematic Review
- Caffeine and Cognitive Functions in Sports: A Systematic Review and Meta-Analysis.
Lorenzo Calvo J, Fei X, Domínguez R, et al. · Nutrients 2021 · Meta-Analysis, Systematic Review
Sponsor: Hikma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.